Lycia Therapeutics Files S-1/A Amendment with SEC
Lycia Therapeutics, Inc. (SEC file no. 0001806540) filed an S-1/A amendment with the SEC on October 20, 2026 (size: 15 MB), following its initial S-1. The revision likely addresses SEC comments or updates clinical-stage financial disclosures.
51CFO view：Frequent S-1/A amendments are typical for biotech IPOs—often addressing R&D capitalization policies, clinical trial cost allocation, and stock-based compensation amortization. The CFO must co-lead accounting policy decisions and disclosure wording, requiring fluency in FDA-SEC regulatory interface and technical financial storytelling.
Lycia Therapeutics, Inc. (SEC file no. 0001806540) filed an S-1/A amendment with the SEC on October 20, 2026 (size: 15 MB), following its initial S-1. The revision likely addresses SEC comments or updates clinical-stage financial disclosures.
Source：SEC EDGAR · S-1 招股书备案
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who runs finance through a SPAC merger?
De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ.
Read →